Thioredoxin (Trx1) is a redox-active protein containing two active site cysteines (Cys32 and Cys35) that cycle between the dithiol and disulfide forms as Trx1 reduces target proteins. Examination of the redox characteristics of this active site dithiol/disulfide couple is complicated by the presence of three additional non-active site cysteines. Using the Redox Western blot technique and MALDI-TOF mass spectrometry, we determined the midpoint potential (E 0 ) of the Trx1 active site (-230 mV) and identified a second redox-active dithiol/disulfide (Cys62 and Cys69) in an alpha helix proximal to the active site, which formed under oxidizing conditions. This non-active site disulfide was not a substrate for reduction by thioredoxin reductase and delayed the reduction of the active site disulfide by thioredoxin reductase. Within actively growing THP1 cells, most of the active site of Trx1 was in the dithiol form while the non-active site was totally in the dithiol form. Addition of increasing concentrations of diamide to these cells resulted in oxidation of the active site at fairly low concentrations and oxidation of the non-active site at higher concentrations. Taken together, these results suggest that the Cys62-Cys69 disulfide could provide a means to transiently inhibit Trx1 activity under conditions of redox signaling or oxidative stress, allowing more time for the sensing and transmission of oxidative signals.
Introduction
Thioredoxin (Trx1 1 ) is a ubiquitous 12 kDa protein that functions as a reductant for ribonucleotide reductase, peroxiredoxins, and transcription factors (e.g. Fos, Jun, NF-kB, p53), controlling key aspects of cell proliferation and survival (1) (2) (3) (4) . The active site of Trx1, WCGPC, is conserved among species from cyanobacteria to humans (5) . The active site cysteines are readily accessible on the surface of the protein and become oxidized to a disulfide upon reduction of a target protein. This disulfide is cycled back to the dithiol by Trx reductase (6) .
Unlike Trx's from lower species, mammalian Trx1 contains additional conserved cysteine residues (at positions 62, 69, and 73 of human Trx1; See Fig. 1 ). Whether these non-active site Cys residues have biologic function is unknown. Cys73 was present as an intermolecular disulfide bond (Trx1 homodimer) in X-ray crystal studies (7) , suggesting a possible function for Cys73. However, a mutant Trx1 bearing a serine at this position still appeared as a homodimer in the crystal structure, suggesting that Cys73 was not essential for dimerization (7) . More recently, S-glutathionylation of Trx1 at Cys73 has been found during oxidative stress (8) . In addition, S-nitrosylation of Cys69 has recently been described (9) .
between glutathione (GSH) redox buffers and E. coli Trx yielded a similar value for E 0 (15) . In the latter approach, the relative amounts of reduced and oxidized Trx were determined by quantification of the number of thiols with Ellman's reagent (dithionitrobenzoic acid; DTNB) because E. coli Trx contains only one redox-active pair of cysteines.
Oxidized and reduced forms of bovine Trx1 have been separated by carboxymethylation of thiols, native gel electrophoresis, and immunoblotting (16) . The fully reduced (fully carboxymethylated) and fully oxidized forms of bovine Trx1 were identified, but intermediate bands on the immunoblot were only identified as "partially carboxymethylated" (16) . In the present report, we have used mass spectrometry to positively identify the forms of human Trx1 that are resolved by this native gel electrophoresis/Western blot (Redox Western blot) method. The results show that the resolved bands include fully reduced Trx1, a band with the active site in the disulfide form, and a band in which the protein has 2 disulfides, one at the active site and the other involving Cys62 and Cys69. The midpoint potential (E 0 ) for the active site was found to be -230 mV. Using this value and Redox Western blot analysis of THP1 cells, the steady state redox (E h ) of Trx1 was -280 mV, a value that is comparable to the E h for
MALDI-TOF MS: Positive-ion MALDI-TOF MS analysis was performed using model
ReflexIII delayed-extraction MALDI-TOF mass spectrometer (Bruker Daltonics, Billarica, MA) equipped with a 337 nm nitrogen laser; alpha-cyano-4-hydroxycinnamic acid (MALDI-Quality, Hewlett-Packard) was used as the matrix.
Monobromobimane labeling and fluorescence detection of Trx1: For some experiments, samples were treated with 100 mM monobromobimane (mBBr, Molecular Probes, Eugene, OR) instead of IAA. Labeling was carried out in the guanidine-Tris solution for 30 min at 37°C, and excess mBBr was removed with G-25 MicroSpin columns. The mBBr-labeled samples were digested with trypsin in 50 mM Tris-acetate buffer, pH 8.5
(20 h at 35°C), and then 10% aqueous trifluoracetic acid (TFA; pH<2) was added. The resulting peptides were separated by microbore RP-HPLC on an Applied Biosystems model 140A solvent delivery system, using a C18 silica column (1x150 mm, Zorbax-SB300) with a linear gradient of acetonitrile in 0.1% TFA. The fluorescence of the effluent was monitored at an emission wavelength of 380 nm with an excitation wavelength of 290 nm. Eluted peaks were collected, and the identity of the peptide in each peak was established by Edman sequencing (Applied Biosystems, Foster City, CA).
Molecular Modeling: An energy minimization model for Trx1 with a disulfide bond between Cys62 and Cys69 was developed with the InsightII/Discover software package (Accelrys Inc., San Diego). The starting coordinates were from the reduced human crystal structure, PDB entry 1ERT. The model was first energy minimized using the cvff parameter file without forming any disulfide linkages. The Cys62-Cys69 disulfide was then formed and the model further minimized. Ribbon drawings of the resulting models were prepared using MOLSCRIPT (21), BOBSCRIPT (22) and RASTER3D (23).
Watson et al. (24) .
Results
Separation of reduced and oxidized Trx1: Purified Trx1 was reduced with DTT or oxidized with diamide, carboxymethylated with IAA, separated by native PAGE, and visualized by Coomassie staining (Fig. 2) . DTT-treated Trx1 moved as a single band (labeled as Band 3 in Fig. 2 ). Diamide-treated Trx1 also moved as a single band (labeled Band 1 in Fig. 2 ), but migrated more slowly than DTT-treated Trx1. Fig. 3A shows the MALDI-TOF mass spectra of tryptic digests of reduced and oxidized Trx1. The predicted and observed masses of the relevant peptides are given in (Fig. 3B ).
Redox states of Trx1 after equilibration with redox buffers: Purified Trx1 was equilibrated with 50 mM GSH/GSSG redox buffers over a range of potentials (-270 to -210 mV) likely to be found within cells (25, 26) , carboxymethylated, and separated on a
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native gel, as before (Fig. 4) . The redox potentials of the redox buffers were verified by HPLC analysis of the GSH and GSSG content of the redox buffers at the beginning and the end of the equilibration period; these were found to be unchanged over the course of the equilibration (not shown). Experiments were also performed with GSH/GSSG redox buffers at 5 mM total concentration instead of 50 mM and identical results were obtained.
Because IAA may shift the thiol-disulfide equilibrium of proteins (27) , experiments were performed to compare results obtained with 10 mM and 50 mM IAA. The results were not distinguishable; thus, the conditions used here (50 mM IAA) did not allow significant changes in Trx1 redox state during processing. At -270 mV, the predominant band comigrated with the DTT-treated Trx1. MALDI-TOF analysis showed that this band (Band 3) contained only fully carboxymethylated Trx1 (see Table 1 ). At -240 mV, Trx1 was To provide an independent confirmation of the E 0 of the active site, Trx1 was equilibrated at different redox potentials, labeled with the thiol-specific fluorescent probe mBBr, digested with trypsin, separated by C18 liquid chromatography, and detected by fluorescence ( Fig. 6 ). Eluates corresponding to peaks of fluorescence were collected, and the identities of the peptides were established by Edman sequencing (Table 2 ). Because monobromobimane labels thiols, but not disulfides, the redox dependent change in fluorescence intensity of the peaks corresponding to peptides T4, T6, and T7 was reflective of the oxidation state of the thiols in each peptide. With this analysis, half of the fluorescence of the active site peptide (T4) was lost at a potential of -225 mV. These results are in good agreement with the value of -230 mV from the Redox Western blot approach, and show that the E 0 for the active site of human Trx1 is more positive than that for E. coli Trx, i.e., in the range of -230 mV rather than -270 mV (10, 11) .
Redox dependence of the non-active site disulfide: The mass spectrometry data showed that the oxidized form of Trx1 that moved as Band 1 on the Redox Western contained two disulfide bonds. Band 1 was detected at potentials as low as -270 mV, and the intensity of Band 1 increased at -240 mV and -210 mV. However, there was an overall loss of signal and the appearance of a fourth (minor) band at redox potentials more oxidizing than -210 mV; approximately half of the total signal (Bands 1, 2, and 3) was lost at -150 mV (Fig. 3) . Thus, the E 0 for the non-active site is more positive than -210
mV. The nature of the changes responsible for the loss of signal in the Redox Western at potentials more positive than -210 mV are unclear.
Redox state of endogenous Trx1 in cells: To determine the redox state of intracellular Trx1, extracts from control and oxidant-exposed THP1 human monocytes were analyzed by Redox Western blot (Fig. 7) , and compared to the redox state of Trx1 at known redox potentials (Fig. 4) . About 95% of the Trx1 from proliferating cells was in the fully reduced state, with some Band 2, and no fully oxidized Trx1 (Fig. 7, lane 1) . This caused a 20 mV oxidation of the active site (Fig. 7) .
Modeling of the non-active site disulfide in the Trx1 structure: The crystal structure of fully reduced human Trx1 is known, but not that of the Cys62-Cys69 oxidized structure.
In the reduced structure, the sulfhydryls for Cys62 and Cys69 lie partially buried at opposite ends of a short α-helix, about 10 Å apart. In this conformation, the Cys62-Cys69 disulfide bond cannot form. However, this helix is only loosely attached to the core of the protein through two loops, and this helix, in solution, could dynamically pull away from the protein core and sufficiently unravel to allow disulfide bond formation. We modeled
this possibility starting with the crystal coordinates for the fully reduced protein (PDB entry 1ERT), connecting Cys62 and Cys69, and energy minimizing. The resulting structure ( Fig. 8 ) supports the hypothesis that local unfolding would allow the disulfide to form and substantially alter the structure in this region proximal to the active site.
Reduction of Trx1 mutants by thioredoxin reductase: Earlier studies showed that fully oxidized mammalian Trx1 was much more slowly reduced by thioredoxin reductase than was Trx1 that was oxidized only at the active site (24, 28, 29) . These results imply that oxidation of the non-active site thiols could alter the rate of reduction by thioredoxin reductase and thereby provide a redox mechanism for control of Trx1 function. To determine whether the Cys62-Cys69 disulfide was responsible for the altered reactivity with thioredoxin reductase, a mutant of Trx1 bearing Cys → Ser mutations at positions 62 and 69 was generated and purified (C62,69S). Fig. 9 shows the reduction of wild type and mutant Trx1 by thioredoxin reductase and NADPH according to the reaction NADPH + H + + oxidized Trx1 → NADP + + reduced Trx1. As reported previously (24, 28, 29) , wild type Trx1 exhibited an early lag phase during which it was slowly reduced followed by a period of more rapid reduction. In contrast, C62,69S did not exhibit the lag period; the rate of reduction was greatest initially and slowed only as the amount of substrate (oxidized C62,69S) became limiting. The total amount of NADPH oxidized was consistent with the interpretation that the mutant form contained one less disulfide than the wild type Trx1.
NADPH was reduced per mole of the active site mutant. These results show that there was one disulfide in this mutant without active site thiols and that this non-active site disulfide was reduced by wild type Trx1. Thus, the non-active site disulfide is a substrate for reduction by the active site of Trx1, and the active site is, in turn, reduced by thioredoxin reductase.
Discussion
The three-dimensional structures of the thioredoxins are very similar among different species, even though there are regions of considerable sequence differences (5, 7). The structure of the sequence containing the active site cysteines is also highly conserved;
Cys32 is located at the end of the α2-helix and Cys35 is in the linker region between the α2-and α3-helices (30) . The E 0 of the active site dithiol of Trx1 is -270 mV in E. coli (10, 11) , -240 mV in yeast (12) , and -230 mV in bacteriophage T4 (13) . The present data
show that the active site of human Trx1 has an E 0 of -230 mV, i.e., at the higher end of the range of known values. The redox state of endogenous E. coli Trx has been estimated to be 30% to 60% reduced (19, 31) , although a more recent report has suggested that E.
coli Trx1 is up to 90% reduced (32) . In mammalian systems, bovine Trx1 was completely reduced in endothelial cells (16) , and human Trx1 was 90% reduced in MCF-7 cells (33) and in HaCaT keratinocytes (34). Thus, our results show that human Trx1, like bovine Trx1, is maintained in a more reduced state within cells than is E. coli Trx1, and that the Redox Western blot yields an estimate of the redox state of cellular Trx1 that agrees well with previous estimates.
In addition to the active site cysteines, mammalian Trx1 contains three additional cysteines that are not found in thioredoxins from other species or in mammalian mitochondrial Trx2. Cys62 and Cys69 are within the α3-helix, and Cys73 is on a hydrophobic patch on the surface of the protein (see Fig. 8 ) the structure (14.7 Å 2 for the main-chain atoms vs. 14 Å 2 overall). However, movement of the helix is blocked in the dimer found in the crystal and so does not reflect its unrestricted dynamics. The loops connecting the helix are not restricted in the crystal and have higher temperature factors. Therefore, the possibility of disulfide bond formation between the Cys residues of the α3 helix is supported by the crystal structure.
The formation of a disulfide between Cys62 and Cys69 is predicted to have a profound effect by disrupting the helical structure of the α3 helix of Trx1 (see Fig. 8 ). In cocrystallization experiments, amino acids within this helix were shown to come in contact with Ref-1 and NF-κB peptides (37,38), two substrates for Trx1. Thioredoxin reductase most likely contacts Trx1 in this region as well; when Trx1 was in the homodimer form, stabilized by an intermolecular Cys73-Cys73' disulfide bond in close proximity to the α3-helix, the active site was inaccessible to thioredoxin reductase (29) . The biphasic reduction of the two-disulfide form of Trx1 (see Fig. 9 ) provides further support for the interpretation that the interaction between Trx1 and thioredoxin reductase is sensitive to presence of a non-active site disulfide in the α3-helix. A mutant of Trx1 (C62,69S) that was unable to form the Cys62-Cys69 disulfide was not inactivated as a substrate for thioredoxin reductase by extensive oxidation, highlighting the importance of these two residues. It should be noted that this mutant still contained Cys73 and was thus still capable of forming disulfide-bonded homodimers (29, 35) . Therefore, dimerization was probably not responsible for the early lag phase in the kinetics of reduction by thioredoxin reductase under the conditions used here.
The presence of the non-active site disulfide decreased the rate at which the active site of ND means that the expected mass was not detected. Figure 1 shows the amino acid sequences of the tryptic fragments. T4, T6, and T7 are the Cys-containing fragments.
Carboxymethylation (cm) and Met oxidation (ox) are indicated.
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